DiscoverEagle's Eye View: Your Weekly CV Update From ACC.orgEagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?
Eagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?

Eagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?

Update: 2023-05-24
Share

Description

In this week’s View, Dr. Eagle looks at a patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials that investigated racial differences in quality of life for patients with heart failure treated with SGLT2 inhibitors. He then covers screening for dilated cardiomyopathy in at-risk first-degree relatives. Finally, Dr. Eagle discusses skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction. 

Subscribe to Eagle’s Eye View  

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Eagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?

Eagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?